The 2025 Lancet Commission framework now formally classifies obesity as a chronic, relapsing multisystem disease, and this narrative review synthesizes the pharmacological evidence underpinning that reclassification. Among the headline figures: semaglutide 2.4 mg produces mean body weight reductions of ~14.9%, while the dual GIP/GLP-1 agonist tirzepatide reaches ~20.9%. The SELECT trial's cardiovascular outcome data adds critical weight — a 20% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide, independent of baseline glycemic status, confirming cardioprotection beyond glucose control. Nutraceutical and bioactive compound interventions, by contrast, show modest and inconsistent weight-loss effects across the reviewed literature.
The MACE finding from SELECT is arguably the most paradigm-shifting element here: it positions GLP-1-based therapy not merely as a metabolic corrective but as a primary cardiovascular intervention — a conceptual leap with major implications for cardiologists, not just endocrinologists. The rapid weight rebound upon drug cessation, however, is the field's unresolved liability, confirming that these agents manage rather than cure the underlying biology. This review's framing is largely confirmatory rather than novel — it synthesizes existing trial data rather than generating new findings — and being a narrative (not systematic) review, it carries inherent selection bias risk. For clinicians and patients, the practical takeaway is clear: high-potency pharmacotherapy should be considered a long-term, potentially indefinite commitment, best integrated within a phenotype-matched, multi-tiered care strategy.